Income statement, balance sheet and cash flow statement for the last 9 fiscal years, taken from the XBRL data Vir Biotechnology, Inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2017
FY2019
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Revenue
2.71
10.7
8.09
76.4
1,095
1,616
86.2
74.2
68.6
Cost of revenue
0
0
65.9
146
2.77
0.85
0.03
Gross profit
8.09
76.4
1,030
1,469
83.4
73.4
68.5
Research and development
62.5
100
148
302
448
475
580
506
456
Selling, general and administrative
37.6
70.9
161
162
174
119
92.1
General and administrative
21.7
29.1
37.6
70.9
Operating expenses
84.2
129
186
373
Operating income
-81.5
-119
-178
-297
421
833
-684
-587
-479
Interest income
0.64
2.54
8.51
28.1
87
71.8
40.2
Other non-operating income
0.72
2.33
-3.45
-1.63
129
-78.8
56.1
64.1
41.6
Pre-tax income
-80.8
-116
-175
-299
550
754
-628
-523
-438
Income tax
-10.9
-0.48
0.15
0.05
21.2
238
-13.1
-1.15
0.22
Net income to minority interests
0
-0.06
0
0
Net income
-69.9
-116
-175
-299
529
516
-615
-522
-438
EBITDA
-81.2
-117
-175
-293
426
840
-665
-573
-468
EPS, basic
-32.45
-15.12
-5.76
-2.51
4.07
3.89
-4.59
-3.83
-3.16
EPS, diluted
-32.45
-15.12
-5.76
-2.51
3.96
3.83
-4.59
-3.83
-3.16
Shares, basic (weighted)
2.15
7.67
30.3
119
130
133
134
136
139
Shares, diluted (weighted)
2.15
7.67
30.3
119
133
135
134
136
139
Balance sheet
FY2017
FY2019
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
188
47.6
109
437
348
849
242
223
232
Short-term investments
50.8
274
300
217
1,522
1,271
678
229
Receivables
0
773
0
Other current assets
8.58
13.4
27.5
73
26.4
7.6
0.1
45.1
Total current assets
118
403
772
1,563
2,519
1,588
1,042
514
Property, plant and equipment
12.3
16.3
17.9
42.8
106
96
63.2
55.6
Lease right-of-use assets
61.9
87.2
82.6
71.2
59.7
62.1
Goodwill
16.9
16.9
16.9
16.9
16.9
16.9
16.9
16.9
Intangible assets
36.9
35.7
33.8
33.3
32.8
22.6
8.12
7.85
Long-term investments
24.3
0
201
23.9
105
190
315
Total assets
192
512
919
1,954
2,802
1,919
1,399
1,003
Accounts payable
6.47
5.88
5.08
6.52
6.42
6.33
5.08
9.8
Accrued liabilities
14.5
26.5
Deferred revenue
8.76
6.18
6.45
98.2
15.5
64.9
12.6
0
Total current liabilities
39.9
59.2
99.1
341
511
175
120
92.8
Lease liabilities
66.6
134
124
112
90.1
89.1
Other non-current liabilities
1.59
3.57
3.85
2.54
11.1
15.8
14.6
21.6
Total liabilities
61.6
88.1
202
522
724
329
248
238
Paid-in capital
14.7
793
1,385
1,572
1,710
1,829
1,912
1,965
Retained earnings
-194
-369
-667
-139
377
-238
-760
-1,198
Other comprehensive income
-0.01
-0.6
-1.28
-1.1
-9.12
-0.82
-1.72
-2.06
Shareholders' equity
-68.9
-179
424
717
1,432
2,078
1,590
1,150
765
Minority interests
0
Total equity
-68.9
-179
424
717
1,432
2,078
1,590
1,150
765
Total liabilities and equity
192
512
919
1,954
2,802
1,919
1,399
1,003
Shares outstanding
8.86
108
127
131
133
135
137
139
Cash flow statement
FY2017
FY2019
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
-69.9
-116
-175
-299
529
516
-615
-522
-438
Depreciation and amortization
0.26
1.62
3.29
4.4
5.28
6.78
19.5
14.6
11.7
Stock-based compensation
4.78
5.05
8.72
27.6
83.8
102
111
78.5
49.1
Deferred income tax
-10.9
-0.5
-0.05
15.2
-15.2
-1.06
-2.95
0.3
Change in receivables
0
-773
770
-0.57
-6.51
Change in payables
2.01
1.47
0.96
-0.79
-0.17
0.8
0.73
-0.99
5
Cash from operations
-66.4
-94.1
-130
-191
-47.6
1,663
-779
-446
-392
Capital expenditures
-2.74
-8.19
-8.94
-6.55
-21.8
-68
-21.6
-7.3
-4.83
Acquisitions
-27.3
Purchases of investments
-123
-644
-404
-420
-1,477
-2,016
-1,235
-886
Sales and maturities of investments
72.6
397
400
301
352
2,202
1,739
1,201
Cash from investing
-30
-60.4
-256
-9.86
-141
-1,193
165
499
310
Stock issued
0.58
126
323
0
0
3.48
0.79
1.35
Cash from financing
271
25
449
529
100
34.8
7.48
4.39
3.79
Net change in cash
175
-130
63.5
329
-88.1
505
-607
57.4
-77.6
Free cash flow
-69.1
-102
-139
-197
-69.4
1,595
-800
-454
-397
Income taxes paid
0
0
-252
2.68
0.79
2.42
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $10.66 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Operating margin
-92.4%
Operating income / revenue.
EBITDA margin
-88.7%
EBITDA (operating income + depreciation and amortization) / revenue.
Pre-tax margin
-82.9%
Pre-tax income / revenue.
Net margin
-83.0%
Net income / revenue.
FCF margin
-67.1%
Free cash flow (cash from operations - capital expenditures) / revenue.
Operating cash flow margin
-66.8%
Cash from operations / revenue.
Return on equity (ROE)
-25.6%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-20.7%
Net income / average total assets.
Return on invested capital (ROIC)
-31.5%
Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
R&D / revenue
159.6%
Research and development expense / revenue.
SG&A / revenue
32.8%
Selling, general and administrative expense / revenue.
Stock-based pay / revenue
15.5%
Stock-based compensation (from the cash flow statement) / revenue.
Capex / revenue
0.4%
Capital expenditures / revenue.
D&A / revenue
3.7%
Depreciation and amortization / revenue.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
-7.6%
Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 3y
-65.1%
Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Revenue CAGR, 5y
-2.1%
Compound annual growth of revenue over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Gross profit growth, 1y
-6.6%
Gross profit vs the same period a year earlier. Only from a positive base.
Gross profit CAGR, 3y
-64.0%
Compound annual growth of gross profit over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Gross profit CAGR, 5y
-2.1%
Compound annual growth of gross profit over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Book value growth, 1y
-33.5%
Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y
-28.3%
Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value CAGR, 5y
1.3%
Compound annual growth of book value over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y
-28.3%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
-29.0%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
1.8%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
1.7%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
0.9%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
3.1%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
6.04x
Current assets / current liabilities.
Quick ratio
5.57x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
5.57x
(Cash + short-term investments) / current liabilities.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Revenue per share
$1.80
Revenue / diluted weighted shares.
FCF per share
-$1.21
Free cash flow / diluted weighted shares.
Operating cash flow per share
-$1.20
Cash from operations / diluted weighted shares.
Book value per share
$5.81
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/S
5.95x
Market cap / revenue.
P/B
1.84x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
1.88x
Market cap / tangible book value, when positive.
EV/Sales
4.21x
Enterprise value / revenue.
FCF yield
-11.3%
Free cash flow / market cap.
Earnings yield
-14.0%
Net income / market cap (the inverse of P/E).
What was Vir Biotechnology, Inc.'s revenue in fiscal 2025?
Vir Biotechnology, Inc. reported revenue of $68.6M for fiscal 2025, 7.6% lower than the year before.
Was Vir Biotechnology, Inc. profitable in fiscal 2025?
No. It reported a net loss of $438.0M.
How much free cash flow did Vir Biotechnology, Inc. generate in fiscal 2025?
Cash from operations of $391.8M minus capital expenditures of $4.8M left free cash flow of -$396.6M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.